Exocrine Pancreas Carcinoma — Trials

Exocrine Pancreas Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 358
Recruiting: 209
Ph III recruiting: 23
Growth YoY: +41.4%
Industry share: 41%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 101–112 of 112 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00091026	Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer	completed	Phase 2	143	National Cancer Institute (NCI)NIH	1	May 15, 2014	clinicaltrials
NCT01124786	A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	completed	Phase 2	367	Clovis Oncology, Inc.INDUSTRY	15	Apr 17, 2014	clinicaltrials